Recent trends in clinical trials reveal a significant shift from traditional randomized controlled trials (RCTs) to alternative trial designs, particularly in the field of cell and gene therapies. The complexity of these therapies, including unique administration methods and patient populations, often makes RCTs inadequate. Instead, designs like single-group assignment, adaptive, and basket trials are gaining traction, allowing for more flexibility and faster data acquisition. Experts emphasize that such innovative designs can expedite the development of new treatments without compromising data quality. Regulatory bodies like the FDA are largely supportive of these approaches, highlighting the need for a more unified framework for alternative trials to enhance industry standards.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.clinicaltrialsarena.com/features/cell-gene-therapy-trialdesign/
